Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Terminated 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 1Gynecologic 1

Conditions

Colorectal Neoplasms 23Pancreatic Neoplasms 10Colonic Neoplasms 8Stomach Neoplasms 7Esophageal Neoplasms 7Rectal Neoplasms 5Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 5Adenocarcinoma Of Esophagus 5Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Cholangiocarcinoma 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Neoplasms 3Endometrial Neoplasms 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Melanoma 2Lung Neoplasms 2Gastrointestinal Neoplasms 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Urothelial Carcinoma of the Bladder 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1Solid Tumors 1Small Bowel Adenocarcinoma 1Sarcoma, Ewing 1

Interventions

Gemcitabine 5Cisplatin 5Oxaliplatin 4Magnetic Resonance Spectroscopy 4Leucovorin 4Fluorouracil 4durvalumab 3Taxes 3futibatinib 2fludarabine 2Specimen Handling 2Platinum 2Paclitaxel 2Nivolumab 2Irinotecan 2Folfox protocol 2Fluorodeoxyglucose F18 2Carboplatin 2Biopsy 21,2-diaminocyclohexaneplatinum II citrate 2zimberelimab 1ulixertinib 1tocilizumab 1tivozanib 1tislelizumab 1regorafenib 1pevonedistat 1pemigatinib 1pembrolizumab 1olutasidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Cholangiocarcinoma × Fluorouracil × 30 days × Clear all
NCT07619313 2026-06-04

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

Jonsson Comprehensive Cancer Center

Phase 1 Not yet recruiting
46 enrolled
Gastrointestinal

Pancreatic Neoplasms, Cholangiocarcinoma

NCT05712356 2026-05-26

BOLSTER

Lisata Therapeutics, Inc.

Phase 2 Terminated
66 enrolled 12 charts
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Disease Progression

NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT04421820 2026-05-18

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Bold Therapeutics, Inc.

Phase 1/2 Recruiting
220 enrolled
Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡